martes, 2 de septiembre de 2014

NOVARTIS: Joe Jimenez no espera que le "copien"...


"Para 2020 se estima 
perderán la patente fármacos biológicos 
por valor de 100.000 millones de dólares, 
lo que nos da una idea 
de la importancia de este mercado" 

Rebecca Guntern / SANDOZ

(Reuters) - Swiss drugmaker Novartis AG does not expect copycat versions of biotech drugs to play an important role in the healthcare system for another three to five years, its chief executive said on Monday. 

Novartis' generics unit Sandoz is the No. 1 player in the field of copycat medicines, known as biosimilars because they are copies of biotech medicines made from living cells that cannot be replicated exactly. 

Chief Executive Joe Jimenez said biosimilars generated about$500 million in sales for Novartis and were growing at a rate of about 20 percent per year. 

"I think in two to three years you're not going to see a big difference," Jimenez told reporters gathered at Novartis' Basel headquarters for an event about the healthcare challenges of an aging population. 

But he said he expected an "inflection point" following big biosimilar launches in 2017, 2018 and 2019, when many high-priced antibody drugs, which are among the pharmaceutical industry's biggest sellers, will lose patent protection. 

Ver

"By the year 2020, which is just five years from now, you're going to see a big impact," Jimenez said. 

Several companies, including include Israel's Teva and Celltrion of South Korea, are racing to develop biosimilars ahead of looming patent expiries on blockbuster biotech medicines for treating cancer and autoimmune diseases. 

As the global population ages, drugmakers such as Novartis are betting on a growing use of biosimilars as cash-strapped healthcare systems look for ways to cut spending. 

 Ver

But uncertainties over the U.S. regulatory framework for biosimilars, plus high manufacturing costs and the need to run clinical trials to win approval, have caused delays. 

Novartis' local rival Roche has repeatedly pushed back forecasts for when its expensive biotech cancer medicines will face generic competition. 

Roche now expects to see biosimilar competition for its blood cancer drug MabThera, which lost patent protection at the end of last year in Europe, from 2016. 
 (Reporting by Caroline Copley; editing by David Clarke)

Ver Biosimilares en PHARMACOSERÍAS

Menos mal que... vamos mal (XXVII): 5 géants de la pharma réalisent au total plus de $210,5 milliards

 
 
 
 
Ver: 
Le grand chambardement de l’industrie pharmaceutique /Le Temps

domingo, 31 de agosto de 2014

H.A. una bomba que se activa con el abandono de la terapia...


Dra Julia Hauger-Klevene

Profesor Roland Gugler

En agosto de 1979 (justo hoy hace 35 años), como Product Manager en H.A. (Sandoz Venezuela), desarrollamos esta campaña de sensibilización ante el abandono de la terapia y, consecuentemente, las ventajas que aportaba Viskaldix.
La idea nace de un hecho violento ocurrido pocos años atrás en Barcelona (España)


El horror del asesinato de José María Bulto en Barcelona...

  Ver


Aquel día de mayo tres hombres asaltaron una vivienda de la calle de Muntaner y adosaron al cuerpo del industrial Bultó una bomba. Él estaba comiendo, como acostumbraba, en casa de un familiar. Le exigieron 500 millones de entonces y le advirtieron que si intentaba desprendérsela la bomba explotaría. Cuando los terroristas huyeron, dejando la bomba y un pliego de instrucciones, el industrial decidió volver a su casa. El chófer le esperaba abajo. Durante el camino le fue contando lo que había pasado y aún le animó a que palpara la bomba. En cuanto llegó a la casa dio instrucciones nerviosas, pero precisas, al servicio: la primera que avisaran a su hijo. Y luego subió por la escalera interior hasta sus habitaciones. (Más)

 El posterior (26.01.1978) del alcalde Viola, en iguales circunstancias, también por grupos independentistas catalanes


Click sobre imagen para ampliar

Ver: La Vanguardia/Adolfo Arranz


Ver también:

Literaturas vendedoras

sábado, 30 de agosto de 2014

Palabras: Procrastinación

La procrastinación (del latín: pro, adelante, y  crastinus, referente al futuro), postergación o posposición es la acción o hábito de retrasar actividades o situaciones que deben atenderse, sustituyéndolas por otras situaciones más irrelevantes o agradables. 




Se trata de un trastorno del comportamiento que tiene su raíz en la asociación de la acción a realizar con el cambio, el dolor o la incomodidad (estrés). Éste puede ser psicológico (en la forma de ansiedad o frustración), físico (como el que se experimenta durante actos que requieren trabajo fuerte o ejercicio vigoroso) o intelectual. El término se aplica comúnmente al sentido de ansiedad generado ante una tarea pendiente de concluir. El acto que se pospone puede ser percibido como abrumador, desafiante, inquietante, peligroso, difícil, tedioso o aburrido, es decir, estresante, por lo cual se autojustifica posponerlo a un futuro sine die idealizado, en que lo importante es supeditado a lo urgente.(Ver)

Adelantándose al... 


 Ver también:
Preferiría no hacerlo: cómo resistirse a la procrastinación en 11 laxos mandamientos

viernes, 29 de agosto de 2014

Ratón de biblioteca: Els medicaments i jo / Fundació Dr. A. Esteve



 
¿Qué es un medicamento? ¿Cómo actúa? ¿Cómo se descubren y se fabrican? Para acercar el funcionamiento de los medicamentos a los más jóvenes, la Fundación Dr. Antonio Esteve edita en catalán el libro Els medicaments i jo (Los medicamentos y yo).

Mediante ilustraciones divulgativas a cargo de Marta Capdevila, el libro explica cómo actúan los medicamentos en nuestro organismo, los diferentes tipos de administración, las reacciones adversas y los procesos de investigación y fabricación de los fármacos, así como las instituciones nacionales e internacionales que los regulan. 

A continuación, puedes descargarte Els medicaments i jo completo o por capítulos o bien solicitar tu ejemplar impreso haciendo click en Solicitar publicación.


jueves, 28 de agosto de 2014

Terapias de los sentidos. Desnudarse (II).../ Undressme

Two strangers kissing for the first time has now reached a new level. Now, it’s time for them to undress each other and get in bed together! 

Filmmaker Tatia Pilieva’s “Undress Me”, the sequel to her popular “First Kiss” video, was released on July 10 and it already has accumulated nearly 2 million views on YouTube.

Ver:

FIRST KISS Tatia Pilieva / Día Internacional del beso


"I asked strangers to undress each other and get in bed. Nothing else. No rules," Pilieva writes in the video description. 

All His Trumpet Playing Paid Off!: Jill Duggar Gushes About Her First Kiss With Husband Derick Dillard 

The three-minute video starts off with a description of the purpose of the video: “In 1957, William Masters and Virginia Johnson began asking men and women to undress for science. In 2014, we celebrate their groundbreaking research with 20 strangers undressing each other for fun.” 

We then watch as 20 strangers meet for the first time, start to take each other’s clothes off, end up in bed—and finally…you’ll have to watch the video below to see what happens in the end.



Ver anterior: 
Terapias de los sentidos. Desnudarse (I)...

miércoles, 27 de agosto de 2014

Para_Pharma_Lia: Foria*

'Introducing medicines, compounds and 
different drugs through the vagina 
is something that both modern doctors 
and doctors throughout history have done,

Matthew Gerson, creator of Foria 


Foria* is a first of its kind all natural sensual enhancement oil thoughtfully designed for women - a blend of nourishing liquid coconut oil and lab-tested cannabis oil from California-grown marijuana. Our proprietary formula was inspired by the historical use of cannabis as an aphrodisiac in traditional cultures around the world. This ancient wisdom has been validated by the recent groundswell of scientific research into the health benefits of marijuana. Foria harnesses the complex powers of marijuana to create a potent “therapeutic aphrodisiac.” Because we believe that health and pleasure are naturally inseparable, we chose to make Foria with 100% natural liquid coconut oil. Besides being delicious to eat, our coconut oil has a naturally low pH that is great for skin care and ideal for maintaining a healthy vaginal pH - one key to fighting off yeast and bacteria - thereby promoting natural harmony and balance within the body. 

 Ingredients 

Medical Cannabis Oil (approximately 60 mg THC and other cannabinoids), Liquid Coconut Oil. Each 1 ounce bottle contains approximately 30 servings. 
Gluten-Free, Vegan, Sugar-Free, Chemical & Pesticide-Free, No Animal Testing, 100% Natural and, of course, Edible. 




How to Use
  • Apply 4-8 sprays directly onto the clitoris, inner and outer labia, and inside the vagina. 
  • Each spray contains approx. 2 mg THC. 
  • Allow at least 30 minutes to relax and absorb the medicine - a great time for foreplay or self massage. Pleasure yourself alone or with a partner as you desire. 
  • For more information, please visit our FAQ 
  • As with all use of medical marijuana, plan your day accordingly and be safe. 

Why Foria 

The pleasure we experience, whether alone or with a partner, is a deeply enriching and healing part of our lives. Foria was created to benefit women's health and well-being by opening the door to natural, euphoric pleasure. As an all-natural plant-based medicinal, Foria works with your body to facilitate unique wellness experiences. For some women, it may awaken arousal and heighten sensation making orgasms more intense, fuller, or easier to access. For others, it can help promote natural lubrication, reduce pain and tension, and create the relaxation necessary for sensual experience, or restorative rest. Foria works with you, wherever you might find yourself on the pleasure spectrum. 


 Ver

Who We Are 

Aphrodite Group is a California medical marijuana collective - a group of patients and caregivers who have come together to provide safe, secure access to the highest quality medical marijuana. Our collective is dedicated to empowering women to access their full pleasure and well-being through natural therapeutics.



(*) Foria es el nombre de las flores femeninas de la cannabis